H.C. Wainwright analyst Ed Arce assumed coverage of Synlogic with a Buy rating and $5 price target. Synlogic is a late-stage clinical biotech company focused on the design and development of genetically engineered therapies for both rare and common diseases, the analyst tells investors in a research note. The firm says SYNB1934 has the potential to be the first oral, non-systemic agent for phenylketonuria.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SYBX:
- Synlogic price target lowered to $5.50 from $7.00 at Chardan
- Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
- Synlogic reports Q4 EPS (24c), consensus (25c)
- Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
- Synlogic receives positive EMA opinion on orphan designation for SYNB1934
